The Claim
In patients with early-stage Alzheimer’s disease treated with weekly 7 mg rapamycin, pre-dose trough concentrations are consistently below 2 ng/mL and remain under the established immunosuppressive threshold of 5 ng/mL, indicating a lower risk of systemic immunosuppression with this dosing regimen.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
People with early Alzheimer’s who take 7 mg of rapamycin every week seem to have low levels of the drug in their blood before their next dose—so low that it probably won’t weaken their immune system.
See the scientific wording
In patients with early-stage Alzheimer’s disease receiving weekly 7 mg rapamycin, pre-dose trough concentrations remain below 2 ng/mL and below established immunosuppressive thresholds (5 ng/mL), suggesting a lower risk of systemic immunosuppression with this dosing regimen.
What the research says
1 studyStudy: Pharmacokinetic analysis of intermittent rapamycin administration in early-stage Alzheimer's Disease
The study gave Alzheimer’s patients a weekly 7 mg dose of rapamycin and found that the drug levels in their blood before the next dose were too low to cause significant immune suppression, which supports the claim.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.